ArticleBMC infectious diseases2026
Development of in-house PCR assays and cross-sectional molecular surveillance of infectious pathogens in adverse pregnancy outcomes and neonatal sepsis in central India.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdverse pregnancy outcomes (APOs), including spontaneous abortion, stillbirth, and neonatal sepsis, are major contributors to maternal and neonatal morbidity and mortality worldwide, particularly in low- and middle-income countries. Infectious agents are increasingly recognized as key, yet underdiagnosed, etiological factors in APOs. The study was undertaken with the following objectives: (1) To develop and validate in-house real-time PCR assay to detect a broad spectrum of infectious agents beyond standard TORCH pathogens. (2) To conduct cross-sectional molecular surveillance to assess the prevalence of pathogens of interest in patients with adverse pregnancy outcomes and neonatal sepsis at a tertiary care hospital in Central India.
methodsThis cross-sectional study was conducted at two tertiary care centres in Bhopal, India. Clinical samples (blood, urine, placental tissue, Cerebrospinal fluid) were collected from women with cases of Adverse Pregnancy Outcome. Real-time PCR assays targeting Brucella spp., Human Parvovirus B19, Enterovirus, Cytomegalovirus, Epstein-Barr Virus, Hepatitis E Virus, Listeria monocytogenes, and other pathogens were developed and validated against commercial CE-IVD kits.
resultsA total of 99 cases of adverse pregnancy outcomes and 27 neonatal sepsis cases were analysed. The assay demonstrated 90-99.3% amplification efficiency and a detection limit of 1–6 copies/reaction. Pathogen detection rates ranged from 44.2% to 60.3%. Brucella spp. (12-19.2%), Enterovirus (5.2–15.6%) was the most prevalent infection. Neonatal infections were detected in 44.4% of neonatal sepsis cases, with co-infections observed in 14.8% of affected neonates.
conclusionThe study underscores the burden of underrecognized pathogens in adverse pregnancy outcomes and neonatal sepsis, highlighting the diagnostic value of molecular testing in prenatal and neonatal care. Integration of broader infectious screening into routine antenatal care may facilitate earlier interventions and improve outcomes in endemic settings.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.